뎅기열 백신 시장 : 백신 종류별, 제형별, 연령층별, 유통 경로별, 최종사용자별 - 세계 예측(2026-2032년)

The Dengue Vaccine Market was valued at USD 580.39 million in 2025 and is projected to grow to USD 635.93 million in 2026, with a CAGR of 9.43%, reaching USD 1,091.16 million by 2032.

A concise orientation to the evolving scientific, regulatory, and delivery dynamics that are reshaping dengue vaccine priorities across public health and commercial stakeholders

The global trajectory of dengue vaccine development has accelerated in recent years, driven by advances in immunology, renewed public health urgency, and evolving regulatory approaches. Clinical programs that were once nascent have matured into phase III trials and regional registrations, while safety concerns and post-implementation surveillance have sharpened policymaker scrutiny. Concurrently, improvements in manufacturing platforms and a deeper understanding of serostatus-related risks have reshaped clinical positioning and target populations.

As dengue continues to exert a heavy burden across tropical and subtropical regions, health systems and private stakeholders are re-evaluating prevention strategies. Vaccination is increasingly seen as a complement to vector control and diagnostic strengthening, rather than a standalone solution. This shift requires more nuanced commercial and public health planning to align product profiles with the epidemiology of serotypes, age cohorts, and local healthcare delivery models.

Consequently, decision-makers are placing higher value on granular evidence that links vaccine performance to real-world implementation realities. Translating clinical trial data into policy-relevant guidance necessitates robust post-marketing safety monitoring, adaptive immunization schedules where appropriate, and coordinated stakeholder engagement to build confidence among clinicians and communities. The introduction of new vaccine candidates has therefore prompted a strategic re-think across manufacturers, regulators, and payers about how to prioritize access, distribution, and long-term surveillance in a rapidly evolving landscape.

How scientific advances, regulatory recalibration, and distribution innovation are converging to redefine strategic pathways for dengue vaccine implementation and uptake

The dengue vaccine landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing public expectations. Advances in vaccine platforms have enabled candidates with broader serotype coverage and altered reactogenicity profiles, prompting regulators to apply differentiated approval pathways that weigh serostatus and risk mitigation measures. Parallel to these technical shifts, stakeholder expectations have matured: policymakers now demand stronger post-authorization safety data, and communities expect transparent risk communication and measurable public health impact.

Commercial strategy has also adapted to these changes. Manufacturers are prioritizing scalable production processes, cold-chain innovations, and regional manufacturing partnerships to support faster, more resilient supply. Health systems are exploring targeted immunization approaches that align vaccine indications with local epidemiology, such as age-stratified programs or serostatus-informed deployment where feasible. Meanwhile, integration with diagnostic and surveillance systems has become a priority so that vaccination efforts can be monitored and optimized in near real time.

These dynamics have produced a more complex but also more opportunity-rich environment. Investors and strategic planners must now balance the technical promise of new vaccine constructs against practical considerations of delivery, acceptance, and regulatory constraints. Success will depend on multi-stakeholder collaboration, evidence-driven communication, and agile commercialization models that can respond to emerging safety and effectiveness data as implementation scales.

Assessing how tariff shifts and trade policy adjustments are reshaping supply chain resilience, production decisions, and procurement strategies in the dengue vaccine ecosystem

The imposition of tariffs and trade barriers can materially affect the operational economics and strategic decisions of vaccine developers and distributors. When import duties or ancillary levies target raw materials, specialized equipment, or packaging components, supply timelines can lengthen and procurement costs can rise. These effects are amplified when tariffs intersect with stringent cold-chain requirements or with single-source inputs that lack easy regional substitutes. In such circumstances, manufacturers and purchasers may need to absorb higher landed costs or reconfigure supply routes to preserve access and reliability.

Beyond direct cost implications, tariff regimes have downstream consequences for manufacturing location choices and partnership models. Firms may recalibrate investment to favor facilities in tariff-exempt jurisdictions or accelerate technology transfers to local manufacturers to mitigate recurring tariff exposure. This reorientation has implications for workforce development, quality oversight, and regulatory coordination across multiple authorities. Importantly, tariffs can also affect the economics of different dosage forms; for example, single-dose prefilled syringes may carry distinct import profiles compared with multi-dose vials, shaping product selection and procurement strategy for national immunization programs.

Policy responses and commercial mitigations typically include pursuing tariff exemptions for essential public health goods, advocating for harmonized trade treatments for biologics, and exploring duty-drawback or bonded warehousing solutions to ease cash flow pressure. Strategic planning should therefore incorporate scenario analyses of tariff policy trajectories, supply chain redundancy planning, and stakeholder engagement to preserve access while ensuring programmatic sustainability.

Critical segmentation insights that align vaccine attributes, delivery channels, end-user capacities, dosage logistics, and age-specific needs to practical deployment strategies

Segment-driven strategy is essential because product performance, distribution needs, end-user expectations, dosage logistics, and age-targeted uptake each vary in ways that influence adoption and delivery models. Based on Vaccine Type, analysis must differentiate live attenuated candidates from recombinant subunit constructs because their immunogenicity profiles, contraindications, and manufacturing footprints differ; these distinctions influence provider counseling and post-marketing safety monitoring. Based on Distribution Channel, vaccines supplied through hospital pharmacies, online pharmacies, and retail pharmacies will encounter distinct logistics requirements, regulatory oversight, and patient engagement practices, so distribution strategy must be tailored accordingly.

Based on End User, clinics, hospitals, and research institutes have varying capacities for cold-chain maintenance, patient screening, and adverse event reporting, which will shape training, support, and surveillance investments. Based on Dosage Form, multi-dose vials, prefilled syringes, and single-dose vials each present trade-offs between wastage, cold-storage footprint, and point-of-care convenience; procurement teams should weigh these factors against clinic throughput and waste-management capacities. Based on Age Group, strategies for adolescents, adults, and children must reflect immunization schedules, consent frameworks, and communication approaches that differ across caregivers, schools, and workplaces.

Integrating these segmentation lenses enables stakeholders to prioritize product portfolios, tailor distribution partnerships, and design targeted education campaigns. Combining product-specific attributes with channel and end-user realities will improve alignment between clinical potential and real-world performance, thereby supporting more efficient deployment and higher uptake.

Regionally calibrated perspectives that reconcile epidemiology, regulatory practice, and delivery capabilities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional differentiation remains a defining feature of successful dengue vaccine strategies because epidemiology, regulatory systems, infrastructure, and payer expectations vary substantially. In the Americas, public immunization programs and urban transmission settings require approaches that integrate municipal health services, school-based delivery, and active community engagement to address historical vaccine hesitancy and to ensure coverage across diverse urban and rural populations. In contrast, Europe, Middle East & Africa presents a heterogeneous regulatory mosaic where some jurisdictions focus on stringent pre-authorization evidence while others prioritize access through emergency or conditional pathways; adaptive regulatory engagement and region-specific safety data can accelerate uptake in receptive national programs.

Asia-Pacific contains many of the highest-burden areas and therefore presents both urgent need and rapid policy interest in vaccination. Implementation in this region often necessitates coordination with large-scale national immunization programs, complex public-private partnerships, and robust surveillance networks to monitor serotype dynamics. Across all regions, considerations such as local manufacturing capacity, cold-chain robustness, and supplier diversity influence whether procurement favors long-established global suppliers or regional manufacturing collaborations.

Successful regional strategies blend clinical evidence with pragmatic delivery planning, regulatory dialogue, and stakeholder communication tailored to local sensitivities. A one-size-fits-all approach is unlikely to perform; instead, regionally calibrated plans that respect local health system capacities, policy priorities, and cultural contexts will yield more sustainable outcomes.

Insight into how corporate strategies, manufacturing partnerships, and regulatory positioning are determining competitive advantage and supply resilience among dengue vaccine developers

Company strategies in the dengue vaccine area reflect a mix of platform specialization, clinical portfolio decisions, and strategic partnerships. Established pharmaceutical firms have leveraged existing regulatory experience and manufacturing scale to shepherd late-stage candidates and to support complex post-authorization commitments. Emerging biotech organizations and specialty vaccine developers are advancing differentiated constructs and often partner with larger manufacturers for scale-up and global distribution. Contract development and manufacturing organizations have become key enablers, providing fill-finish capacity, analytical support, and cold-chain packaging solutions that allow vaccine sponsors to accelerate availability.

Competitive positioning is increasingly influenced by demonstrated real-world performance, regulatory clarity on serostatus-related use, and the ability to offer integrated delivery solutions that reduce programmatic friction. Firms that invest early in local regulatory engagement, epidemiologic partnerships, and community outreach programs are more likely to achieve broader acceptance. Strategic alliances between global developers and regional manufacturers can unlock supply resilience while satisfying local-content considerations and regulatory requirements.

Intellectual property strategies, licensing agreements, and manufacturing partnerships will continue to shape who can scale production rapidly and who can adapt products to regional needs. For purchasers and partners, the most relevant differentiators will be demonstrated safety in diverse populations, logistical compatibility with recipient health systems, and the flexibility to support targeted deployment models.

Actionable recommendations for senior executives to align evidence generation, supply resilience, regulatory dialogue, and stakeholder engagement for effective vaccine rollout

Industry leaders should adopt a multi-pronged approach that balances clinical evidence generation, supply-chain resilience, regulatory engagement, and stakeholder trust-building to advance sustainable vaccination programs. Prioritize investments in robust post-authorization safety surveillance systems and transparent communication strategies that proactively address concerns about serostatus and adverse events. Simultaneously, diversify manufacturing and supplier relationships to reduce vulnerability to trade disruptions and to facilitate regional supply, including technology-transfer arrangements where possible to strengthen local capacity.

Engage regulators early and consistently to clarify intended use populations, labeling strategies, and required post-market commitments so that approvals can align with implementation timelines. Tailor distribution models to the realities of target delivery channels; for example, align product presentation and cold-chain needs with the capacities of hospital pharmacies, retail outlets, or community clinics. Design age-specific outreach campaigns that reflect caregiver concerns for children, school-based delivery opportunities for adolescents, and workplace or primary-care pathways for adults.

Finally, advocate for policy frameworks that recognize vaccines as critical public health goods, including tariff exemptions, streamlined import procedures, and financing mechanisms that reduce barriers to access. By integrating scientific rigor with pragmatic operational planning and stakeholder engagement, industry leaders can improve the likelihood of successful and equitable vaccine rollouts.

A transparent methodology integrating primary stakeholder interviews, systematic secondary review, triangulated safety and implementation data, and scenario-based risk analysis to inform strategic decision-making

The analysis underpinning this report integrates primary and secondary research techniques designed to produce a defensible, actionable evidence base for decision-makers. Primary inputs include structured interviews with clinicians, supply-chain specialists, regulatory affairs leaders, and public health policymakers, supplemented by advisory-board consultations that contextualize trial data and field experience. Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory documents, safety surveillance reports, and public health guidance to triangulate product profiles and implementation challenges.

Analytical rigor was reinforced by cross-validation of clinical endpoints reported in pivotal studies with pharmacovigilance findings and programmatic observations from regions with active use. Risk assessments evaluated supply-chain fragility, tariff exposure, and cold-chain constraints, while scenario planning explored alternative distribution and manufacturing configurations. Quality assurance measures included source verification, methodologic transparency, and iterative review by subject-matter experts to ensure that interpretations are grounded in available evidence and real-world operational realities.

Limitations of the methodology are acknowledged: evolving clinical data and regulatory determinations can change the evidence base, and local health-system heterogeneity can affect transferability of certain implementation recommendations. To mitigate these limits, the approach emphasizes modular updates and stakeholder validation workshops that refine insights as new data emerge.

A balanced conclusion highlighting the promise of dengue vaccination tied to pragmatic requirements for evidence, logistics, and collaborative implementation to achieve public health impact

Dengue vaccination has moved from a theoretical possibility to an operational priority for many public health systems and commercial stakeholders, but realizing its full potential requires disciplined alignment of science, policy, and logistics. Advances in vaccine constructs and growing regulatory experience have created new opportunities to protect vulnerable populations, yet the path to broad, equitable access is contingent on careful product selection, robust safety monitoring, and supply-chain foresight. Attention to dosage form selection, distribution channel compatibility, and age-targeted strategies will determine how effectively these vaccines translate into population-level benefit.

Policymakers and industry must collaborate to resolve practical barriers such as trade frictions, cold-chain limitations, and heterogeneous regulatory requirements. When these elements are addressed in a coordinated manner, vaccination programs can amplify the impact of vector-control and diagnostic efforts, creating more durable reductions in dengue burden. Ultimately, stakeholder confidence will hinge on transparent communication, measurable implementation outcomes, and adaptive programs that respond to emerging evidence.

The evolving dengue vaccine ecosystem presents meaningful opportunities for public health gains, provided that strategic investments in evidence generation, supply resilience, and stakeholder partnership are sustained and effectively executed.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dengue Vaccine Market, by Vaccine Type

• 8.1. Live Attenuated
• 8.2. Recombinant Subunit

9. Dengue Vaccine Market, by Dosage Form

• 9.1. Multi-Dose Vial
• 9.2. Prefilled Syringe
• 9.3. Single-Dose Vial

10. Dengue Vaccine Market, by Age Group

• 10.1. Adolescents
• 10.2. Adults
• 10.3. Children

11. Dengue Vaccine Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies

12. Dengue Vaccine Market, by End User

• 12.1. Clinics
• 12.2. Hospitals
• 12.3. Research Institutes

13. Dengue Vaccine Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Dengue Vaccine Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Dengue Vaccine Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Dengue Vaccine Market

17. China Dengue Vaccine Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Biological E. Limited
• 18.6. GeneOne Life Science
• 18.7. GlaxoSmithKline (GSK) plc
• 18.8. Johnson & Johnson Services, Inc.
• 18.9. Medigen Vaccine Biologics
• 18.10. Merck & Co. Inc.
• 18.11. Novartis AG
• 18.12. Sanofi Pasteur
• 18.13. Serum Institute of India
• 18.14. Sun Pharmaceutical Industries Ltd.
• 18.15. Takeda Pharmaceutical Company
• 18.16. Vabiotech